Vertriebs- Und Verwaltungskosten Veränderung Datum
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
ALKERMES USD 264.59M 77.4M 2026-03
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
Amgen USD 1.58B 354M 2026-03
Baxter International USD 728M 33M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Biogen USD 554.3M 128.2M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Cara Therapeutics USD 2.19M 2.45M 2025-09
Cipla INR 13.25B 101.8M 2025-12
Dr.Reddys Laboratories INR 26.92B 482M 2025-12
Eisai JPY 119.54B 7.82B 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
Exelixis USD 139.6M 16.58M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Merck USD 2.67B 180M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Takeda JPY 292B 9.21B 2026-03
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Xencor USD 82.12M 65.08M 2026-03